Condition: Multiple Myeloma · Sponsor: Zhejiang University
This clinical trial aims to characterize the safety of OL-101 and establish the recommended dose for future research and to evaluate the efficacy of OL-101 (Dose expansion).
This description comes directly from the study's public registry record.
He Huang, MD, PhD · (+86)13605714822 · hehuangyu@126.com
Yongxian Hu, MD, PhD · (+86)15957162012 · huyongxian2000@aliyun.com
Always discuss trial participation with your own doctor first.
| Beijing Gobroad Boren Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| The Affiliated Hospital of Northwest University Xi'an No.3 Hospital | Xi’an, Shanxi, China | Not Yet Recruiting |
| The first affiliated hospital, College of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06644118